| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
(1,3)Gal Expression in Animals with a Deletion of the 1,3Galactosyltransferase Gene1,2
The Austin Research Institute, Austin Health, Heidelberg, Australia
The production of homozygous pigs with a disruption in the GGTA1 gene, which encodes 
1,3galactosyltransferase (1,3GT), represented a critical step toward the clinical reality of xenotransplantation. Unexpectedly, the predicted complete elimination of the immunogenic Gal(1,3)Gal carbohydrate epitope was not observed as Gal(1,3)Gal staining was still present in tissues from GGTA1–/– animals. This shows that, contrary to previous dogma, 1,3GT is not the only enzyme able to synthesize Gal(1,3)Gal. As iGb3 synthase (iGb3S) is a candidate glycosyltransferase, we cloned iGb3S cDNA from GGTA1–/– mouse thymus and confirmed mRNA expression in both mouse and pig tissues. The mouse iGb3S gene exhibits alternative splicing of exons that results in a markedly different cytoplasmic tail compared with the rat gene. Transfection of iGb3S cDNA resulted in high levels of cell surface Gal(1,3)Gal synthesized via the isoglobo series pathway, thus demonstrating that mouse iGb3S is an additional enzyme capable of synthesizing the xenoreactive Gal(1,3)Gal epitope. Gal(1,3)Gal synthesized by iGb3S, in contrast to 1,3GT, was resistant to down-regulation by competition with 1,2fucosyltransferase. Moreover, Gal(1,3)Gal synthesized by iGb3S was immunogenic and elicited Abs in GGTA1 –/– mice. Gal(1,3)Gal synthesized by iGb3S may affect survival of pig transplants in humans, and deletion of this gene, or modification of its product, warrants consideration.
This article has been cited by other articles:
|
|
 |
|
  F. Casals, A. Ferrer-Admetlla, M. Sikora, A. Ramirez-Soriano, T. Marques-Bonet, S. Despiau, F. Roubinet, F. Calafell, J. Bertranpetit, and A. Blancher Human pseudogenes of the ABO family show a complex evolutionary dynamics and loss of function Glycobiology, June 1, 2009; 19(6): 583 - 591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. POSEKANY, J. E. WILEY, and G. A. GAGNON A Novel Method to Display [gal {alpha}1, 3 gal] Antigens on Human Leukemic Cells for Preparation of Anti-leukemia Vaccines Anticancer Res, June 1, 2009; 29(6): 2387 - 2392. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Uematsu, Y. Shinohara, H. Nakagawa, M. Kurogochi, J.-i. Furukawa, Y. Miura, M. Akiyama, H. Shimizu, and S.-I. Nishimura Glycosylation Specific for Adhesion Molecules in Epidermis and Its Receptor Revealed by Glycoform-focused Reverse Genomics Mol. Cell. Proteomics, February 1, 2009; 8(2): 232 - 244. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. P. Liu, H. Yuan, E. P. Bennett, S. B. Levery, E. Nudelman, J. Spence, G. Pietz, K. Saunders, T. White, M. L. Olsson, et al. Identification of a GH110 Subfamily of {alpha}1,3-Galactosidases: NOVEL ENZYMES FOR REMOVAL OF THE {alpha}3GAL XENOTRANSPLANTATION ANTIGEN J. Biol. Chem., March 28, 2008; 283(13): 8545 - 8554. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Li, S. Teneberg, P. Thapa, A. Bendelac, S. B. Levery, and D. Zhou Sensitive detection of isoglobo and globo series tetraglycosylceramides in human thymus by ion trap mass spectrometry Glycobiology, February 1, 2008; 18(2): 158 - 165. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Watanabe, M. Misawa, T. Matsuzaki, T. Sakurai, T. Muramatsu, T.-a. Yokomine, and M. Sato Production and Characterization of Transgenic Mice Systemically Expressing Endo- -Galactosidase C Glycobiology, January 1, 2008; 18(1): 9 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Misawa, S. Watanabe, S. Ihara, T. Muramatsu, and T. Matsuzaki Accelerated Proliferation and Abnormal Differentiation of Epidermal Keratinocytes in Endo- -Galactosidase C Transgenic Mice Glycobiology, January 1, 2008; 18(1): 20 - 27. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Salio, A. O. Speak, D. Shepherd, P. Polzella, P. A. Illarionov, N. Veerapen, G. S. Besra, F. M. Platt, and V. Cerundolo Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activation PNAS, December 18, 2007; 104(51): 20490 - 20495. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-L. Turcot-Dubois, B. Le Moullac-Vaidye, S. Despiau, F. Roubinet, N. Bovin, J. Le Pendu, and A. Blancher Long-term evolution of the CAZY glycosyltransferase 6 (ABO) gene family from fishes to mammals--a birth-and-death evolution model Glycobiology, May 1, 2007; 17(5): 516 - 528. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. O. Speak, M. Salio, D. C. A. Neville, J. Fontaine, D. A. Priestman, N. Platt, T. Heare, T. D. Butters, R. A. Dwek, F. Trottein, et al. From the Cover: Implications for invariant natural killer T cell ligands due to the restricted presence of isoglobotrihexosylceramide in mammals PNAS, April 3, 2007; 104(14): 5971 - 5976. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Porubsky, A. O. Speak, B. Luckow, V. Cerundolo, F. M. Platt, and H.-J. Grone From the Cover: Normal development and function of invariant natural killer T cells in mice with isoglobotrihexosylceramide (iGb3) deficiency PNAS, April 3, 2007; 104(14): 5977 - 5982. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. I. Godfrey, M. J. McConville, and D. G. Pellicci Chewing the fat on natural killer T cell development J. Exp. Med., October 2, 2006; 203(10): 2229 - 2232. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
